Our B7-H6/CD3 T-cell engager* acts as a bridge that selectively directs the activity of T-cells toward tumor cells that express B7-H6.1
Clinical trials (monotherapy and combination therapy): our B7-H6/CD3 T-cell engager is currently being investigated in a Phase I trial as monotherapy and in combination with ezabenlimab (BI 754091)*, a programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced solid tumors that express B7-H6.2
B7-H6 is a member of the B7 family of immune receptors, which is expressed in several solid tumor indications, such as CRC, NSCLC, HNSCC, hepatocellular, gastric, and pancreatic carcinoma while no to very little expression can be detected in normal tissues.1,3
Mechanism of action
Our B7-H6/CD3 T-cell engager simultaneously binds to cluster of differentiation 3 (CD3) expressed on T cells and B7-H6 expressed on tumor cells resulting in formation of a cytolytic synapse and redirection of the cytolytic activity of T cells towards tumor cells that express B7-H6. Consistent with the mode-of-action, the treatment with B7-H6/CD3 T-cell engager in vivo leads to tumor cell apoptosis, local activation and proliferation of T cells, and cytokine secretion in the tumor tissue, converting a non-inflamed (cold) tumor environment into an inflamed (hot) tumor environment.1
In humanized CRC mouse models, monotherapy with our B7-H6/CD3 T-cell engager resulted in tumor regression which was associated with local activation and proliferation of T cells, secretion of cytokines, and upregulation of the PD-(L)1 pathway in the tumor tissue; therefore, combination with anti-PD-1 agents (such as ezabenlimab) may further enhance the efficacy of the B7-H6/CD3 T-cell engager.1,4
Our B7-H6/CD3 antibody is currently undergoing clinical investigation in a Phase I study as a monotherapy and in combination with ezabenlimab in patients with advanced solid tumors that express B7-H6.2
|Trial number||Phase||Treatment||Patient population||Status|
B7-H6/CD3 T-cell engager (monotherapy and in combination with ezabenlimab [BI 754091])
Advanced / metastatic CRC OR patients with advanced solid tumors having the B7-H6 marker
Hipp S, et al. Presented at: American Association for Cancer Research Annual Meeting 2021; 2021; April 10–15. Philadelphia.
ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/ct2/show/NCT04752215 (Accessed: July 2021).
Brandt C, et al. J Exp Med 2009;206(7):1495–1503.
Hipp S, et al. Cancer Res 2021;81(13 Supplement):56. DOI: 10.1158/1538-7445.AM2021-56.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: August 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue